Clinical Trials
50
Active:2
Completed:17
Trial Phases
4 Phases
Phase 2:3
Phase 3:2
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (39 trials with phase data)• Click on a phase to view related trials
Not Applicable
33 (84.6%)Phase 2
3 (7.7%)Phase 3
2 (5.1%)Phase 4
1 (2.6%)No trials found
News
Skyhawk Therapeutics Initiates Phase 2/3 Trial of SKY-0515 for Huntington's Disease
Skyhawk Therapeutics has dosed the first patient in its Phase 2/3 FALCON-HD trial evaluating SKY-0515, an oral RNA splicing modulator for Huntington's disease treatment.